Diazinon is a compound of defined chemical structure and pharmaceutical significance whose toxicological characterisation supports health-based exposure limit derivation for pharmaceutical manufacturing occupational safety and cross-contamination control. The relationship between molecular structure and biological potency—assessed through structure-activity relationship analysis and experimental pharmacological and toxicological data—determines the OEB classification and the engineering containment requirements governing manufacturing operations involving Diazinon.
The OEB assigned to Diazinon in pharmaceutical manufacturing is determined by structured potency banding based on its pharmacological target, NOAEL from repeat-dose studies, genotoxic classification under ICH M7, and reproductive toxicant status. OEB 1 applies when the OEL exceeds 10 mg/m³; OEB 2 covers 1–10 mg/m³; OEB 3 covers 0.1–1 mg/m³; OEB 4 covers 0.01–0.1 mg/m³; and OEB 5—requiring full isolator containment—applies w
